- Home
- NVOS vs MTEM Comparison
NVOS vs MTEM Comparison
Compare NVOS & MTEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVOS
- MTEM
- Stock Information
- Founded
- NVOS 2000
- MTEM 2001
- Country
- NVOS United States
- MTEM United States
- Employees
- NVOS N/A
- MTEM N/A
- Industry
- NVOS Assisted Living Services
- MTEM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NVOS Health Care
- MTEM Health Care
- Exchange
- NVOS Nasdaq
- MTEM Nasdaq
- Market Cap
- NVOS 5.6M
- MTEM 9.7M
- IPO Year
- NVOS 2017
- MTEM N/A
- Fundamental
- Price
- NVOS $0.23
- MTEM $0.71
- Analyst Decision
- NVOS
- MTEM
- Analyst Count
- NVOS 0
- MTEM 0
- Target Price
- NVOS N/A
- MTEM N/A
- AVG Volume (30 Days)
- NVOS 326.8K
- MTEM 13.4M
- Earning Date
- NVOS 12-12-2024
- MTEM 11-11-2024
- Dividend Yield
- NVOS N/A
- MTEM N/A
- EPS Growth
- NVOS N/A
- MTEM N/A
- EPS
- NVOS N/A
- MTEM N/A
- Revenue
- NVOS $13,516,958.00
- MTEM $25,470,000.00
- Revenue This Year
- NVOS N/A
- MTEM N/A
- Revenue Next Year
- NVOS N/A
- MTEM N/A
- P/E Ratio
- NVOS N/A
- MTEM N/A
- Revenue Growth
- NVOS 1102.98
- MTEM N/A
- 52 Week Low
- NVOS $0.20
- MTEM $0.30
- 52 Week High
- NVOS $3.45
- MTEM $6.48
- Technical
- Relative Strength Index (RSI)
- NVOS 38.13
- MTEM 38.68
- Support Level
- NVOS $0.20
- MTEM $0.31
- Resistance Level
- NVOS $0.31
- MTEM $1.34
- Average True Range (ATR)
- NVOS 0.03
- MTEM 0.14
- MACD
- NVOS 0.00
- MTEM -0.05
- Stochastic Oscillator
- NVOS 27.18
- MTEM 34.48
About NVOS Novo Integrated Sciences Inc.
Novo Integrated Sciences Inc is a medical care company. It provides specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, neurological functions, kinesiology, and others. It has two reportable segments: healthcare services which generates majority of the revenue, and product sales.
About MTEM Molecular Templates Inc.
Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer. Its pipeline products are MT-6402, MT-8421 and MT-0169.